NERV Share Price | Minerva Neurosciences, Inc. Stock Analysis & Recommendation

Q: What does Minerva Neurosciences, Inc. do?

Overview: Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing product candidates for central nervous system (CNS) diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 12.87 Million (Micro Cap)Key Metrics: P/E: 2.00 Dividend Yield: 0.00% Debt Equity: -1.46 Return on Equity: -21.46% Price to Book: -0.44Contact Details: Address: 1601 Trapelo Rd Ste 286, WALTHAM MA: 02451-7337 Tel: ['1 617 6007373', '1 617 6007376'] Fax: 1 302 6365454 Website: http://minervaneurosciences.com/

Q: Is Minerva Neurosciences, Inc. overvalued or undervalued?

As of 2 August 2021, Minerva Neurosciences, Inc. has moved from a valuation grade of very attractive to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued. Key ratios include a P/E ratio of 2.06, an EV to EBIT of -2.91, and a PEG ratio of 0.02, which suggest poor profitability and growth prospects.In comparison to its peers, Veru, Inc. has a P/E of -2.30 and an EV to EBITDA of -1.71, while Outlook Therapeutics, Inc. has a P/E of -0.95 and an EV to EBITDA of -1.28, both indicating challenges in their respective valuations. The negative return of Minerva Neurosciences compared to the S&P 500, particularly a YTD decline of -20.33% versus a gain of 2.44% for the index, further reinforces the notion of overvaluation amidst its deteriorating financial health.

Q: Is Minerva Neurosciences, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Minerva Neurosciences, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The daily moving averages are also mildly bullish, suggesting some upward pressure. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly stance and a bearish monthly stance. The KST is bullish on a weekly basis but mildly bullish monthly, while the Dow Theory indicates a mildly bearish weekly trend with no trend monthly. Overall, the technical stance is mildly bullish but lacks strong confirmation from several indicators.In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a 1-year return of -27.72% versus the S&P 500's 17.14%, and a staggering 3-year return of -77.46% compared to the S&P 500's 70.41%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

35.41 k

Shareholding (Sep 2025)

FII

0.43%

Held by 4 FIIs

DII

71.73%

Held by 28 DIIs

Promoter

0.00%

How big is Minerva Neurosciences, Inc.?

22-Jun-2025

As of Jun 18, Minerva Neurosciences, Inc. has a market capitalization of 12.87 million, with net sales of 0.00 million and a net profit of 6.26 million over the last four quarters. The balance sheet shows shareholder's funds of -25.69 million and total assets of 37.14 million.

View full answer

What does Minerva Neurosciences, Inc. do?

22-Jun-2025

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases, with a market cap of $12.87 million and a recent net profit of -$4 million.

View full answer

Who are in the management team of Minerva Neurosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Minerva Neurosciences, Inc. includes Dr. Remy Luthringer (CEO and Executive Chairman), Mr. William Doyle (Lead Independent Director), and four Independent Directors: Mr. Hans Hasler, Ms. Jeryl Hilleman, Dr. David Kupfer, and Dr. Fouzia Laghrissi-Thode. They oversee the company's strategic direction and governance.

View full answer

Is Minerva Neurosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of August 2, 2021, Minerva Neurosciences, Inc. is considered overvalued with a significant downgrade in investment appeal, reflected by a P/E ratio of 2.06 and a YTD decline of -20.33%, contrasting sharply with the S&P 500's gain of 2.44%.

View full answer

Is Minerva Neurosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Minerva Neurosciences, Inc. shows a mildly bullish technical trend with mixed signals from various indicators, while significantly underperforming the S&P 500 with a 1-year return of -27.72% and a 3-year return of -77.46%.

View full answer

Compare Minerva Neurosciences, Inc. with Similar Stocks

SciSparc Ltd.Societal CDMO, Inc.Clearside Biomedical, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 181 Million ()

P/E

2.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.38

Return on Equity

40.57%

Price to Book

-5.24

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.99%

6 Months

122.97%

1 Year

83.48%

2 Years

-55.3%

3 Years

47.04%

4 Years

-29.67%

5 Years

-84.62%

Minerva Neurosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-14.89%

EBIT to Interest (avg)

-14.70

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.46

Sales to Capital Employed (avg)

0.91

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

37.73%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-0.44

EV to EBIT

-2.91

EV to EBITDA

-2.91

EV to Capital Employed

4.12

EV to Sales

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

-141.66%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (27.84%)

Foreign Institutions

Held by 4 Foreign Institutions (0.43%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -112.00% vs 388.46% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.80",
          "val2": "-4.40",
          "chgp": "36.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "22.50",
          "chgp": "-112.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 104.67% vs 6.54% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.80",
          "val2": "-23.10",
          "chgp": "5.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.60",
          "val2": "8.30",
          "chgp": "-44.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.40",
          "val2": "-30.00",
          "chgp": "104.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.80

-4.40

36.36%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.70

22.50

-112.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -112.00% vs 388.46% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-21.80

-23.10

5.63%

Interest

4.60

8.30

-44.58%

Exceptional Items

0.00

Consolidate Net Profit

1.40

-30.00

104.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 104.67% vs 6.54% in Dec 2023

All Annual Results

Company CV

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc.

Pharmaceuticals & Biotechnology

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Company Coordinates

Company Details

1601 Trapelo Rd Ste 286 , WALTHAM MA : 02451-7337

Tel: 1 617 60073731 617 6007376

http://minervaneurosciences.com/

Registrar Details

Minerva Neurosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Minerva Neurosciences, Inc.?

Watch in Real-Time

What does Minerva Neurosciences, Inc. do?

Who are in the management team of Minerva Neurosciences, Inc.?

Is Minerva Neurosciences, Inc. overvalued or undervalued?

Is Minerva Neurosciences, Inc. technically bullish or bearish?

Compare Minerva Neurosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Minerva Neurosciences, Inc.

Company Coordinates